Shandong Xinhua Pharmaceutical Co (HKSE:00719) Total Receivables: HK$1,629 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00719 Shandong Xinhua Pharmaceutical Co Ltd HKSE:00719
93 GF Score
Price HK$5.99
GF Value HK$7.66
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shandong Xinhua Pharmaceutical Co Total Receivables?

Shandong Xinhua Pharmaceutical Co HKSE:00719 -0.42% 93 Total Receivables is HK$1,629 Mil as of Mar. 2026. GuruFocus rates HKSE:00719 with a GF Score™ of 93/100 and a GF Value™ of HK$7.66 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Shandong Xinhua Pharmaceutical Co's Total Receivables for the quarter that ended in Mar. 2026 was HK$1,629 Mil.

Shandong Xinhua Pharmaceutical Co Total Receivables Related Terms

Shandong Xinhua Pharmaceutical Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Shandong Xinhua Pharmaceutical Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Xinhua Pharmaceutical Co Total Receivables Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,087.17 1,098.05 1,048.39 1,205.56 1,344.32

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,498.15 1,525.59 1,415.30 1,344.32 1,628.73
HKSE:00719
93GF Score
Shandong Xinhua Pharmaceutical Co Ltd HKSE:00719
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Xinhua Pharmaceutical Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$1,629 Mil mean?
Shandong Xinhua Pharmaceutical Co (HKSE:00719) has a Total Receivables of HK$1,629 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors.
Is Shandong Xinhua Pharmaceutical Co's Total Receivables too high?
Shandong Xinhua Pharmaceutical Co's current Total Receivables is HK$1,629 Mil. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's Total Receivables compare to ZTS?
Shandong Xinhua Pharmaceutical Co's Total Receivables of HK$1,629 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. Shandong Xinhua Pharmaceutical Co's current Total Receivables is HK$1,629 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co (HKSE:00719) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$7.66, compared to a current price of HK$5.99 — trading 21.8% below its estimated fair value. The current Total Receivables is HK$1,629 Mil. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (HKSE:00719), the current Total Receivables is HK$1,629 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Xinhua Pharmaceutical Co (HKSE:00719) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued. The current stock price of HK$5.99 is trading 21.8% below its estimated GF Value™ of HK$7.66. GuruFocus considers Shandong Xinhua Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for HKSE:00719:

  • Total Receivables: HK$1,629 Mil
  • GF Value™: HK$7.66 vs. price of HK$5.99 (21.8% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the HKSE:00719 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Xinhua Pharmaceutical Co Business Description

Other Exchanges XIN:Germany000756:China
Address No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
93GF Score

Get the complete analysis for HKSE:00719

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.99
Price
HK$7.66
GF Value